Skip to main content
Premium Trial:

Request an Annual Quote

RXi Begins Second Phase IIa Trial of Anti-scarring Drug


NEW YORK (GenomeWeb) – RXi Pharmaceuticals this week announced the start of a Phase IIa trial of its siRNA-based anti-scarring drug RXI-109 for the prevention of keloid recurrence.

RXI-109 comprises siRNAs designed to inhibit connective tissue growth factor, or CTGF, a protein linked to wound healing and other fibrotic processes. It employs the company's proprietary self-delivering technology, which enables cellular uptake without the need for a delivery vehicle.

In the placebo-controlled Phase IIa study, patients with two keloids — a type of scar composed primarily of collagen — of similar size and location are selected for keloidectomy. After the procedure, the lesions will be closed, and one will be treated with RXI-109. Patients will be followed for six months to evaluate the clinical evolution of the lesions.

This latest study follows the initiation of an ongoing Phase IIa trial of RXI-109 in patients with pre-existing hypertrophic scars. These patients undergo scar-revision surgery, after which one end of the scar is treated and the other end receives placebo.

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.